Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Acute Myeloid Leukemia Market
Acute Myeloid Leukemia Market Size
- Report ID: GMI7991
- Published Date: Jan 2024
- Report Format: PDF
Acute Myeloid Leukemia Market Size
Acute Myeloid Leukemia Market was valued at USD 2.1 billion in 2023 and is estimated to grow at a CAGR of 10.7% between 2024. High market growth can be attributed to factors such as advancement in research and technology, surging government initiatives and policies, early diagnosis coupled with efforts to implement screening programs. Also, increasing prevalence of acute myeloid leukemia (AML) is a significant factor driving the growth of the market.
For instance, according to the American Cancer Society, in 2023, there were about 20,380 new cases of acute myeloid leukemia (AML) in the U.S. alone. Hence, as the population ages, the incidence of AML tends to rise, contributing to a larger patient pool seeking diagnosis and treatment, thereby fostering the market growth.
Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally develop into red blood cells, white blood cells, and platelets. In AML, these abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Acute Myeloid Leukemia Market Size in 2023: | USD 2.1 Billion |
| Forecast Period: | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR: | 10.7% |
| 2024 – 2032 Value Projection: | USD 5.1 Billion |
| Historical Data for: | 2018 – 2023 |
| No. of Pages: | 150 |
| Tables, Charts & Figures: | 257 |
| Segments covered: | Disease Type, Treatment Type, Route of Administration, End-user, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Acute Myeloid Leukemia Market Scope
